

Vutrisiran: Self-Administration

The following information is provided in response to your unsolicited inquiry. It is intended to provide you with a review of the available scientific literature and to assist you in forming your own conclusions in order to make healthcare decisions. This document is not for further dissemination or publication without authorization.

The full Prescribing Information for AMVUTTRA® (vutrisiran) is provided [here](#). Alnylam Pharmaceuticals does not recommend the use of its products in any manner that is inconsistent with the approved Prescribing Information. This resource may contain information that is not in the approved Prescribing Information.

If you are seeking additional scientific information related to Alnylam medicines, you may visit the Alnylam US Medical Affairs website at RNAiScience.com.

SUMMARY

- AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.¹
- Given the infrequent dosing schedule, administration by a healthcare professional was deemed the best way to ensure consistent, proper injection technique.

INDEX

[Label Information](#) – [Clinical Data](#) – [Abbreviations](#) – [References](#)

AMVUTTRA PRESCRIBING INFORMATION – RELEVANT CONTENT

The DOSAGE AND ADMINISTRATION section provides the following information¹:

Administration Instructions

AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.

CLINICAL DATA

HELIOS-A Study

HELIOS-A was a phase 3, global, randomized, open-label study designed to evaluate the efficacy and safety of vutrisiran in patients with hATTR-PN. Patients were randomized (3:1) to receive either vutrisiran 25 mg every 3 months by subcutaneous injection (n=122) or patisiran 0.3 mg/kg every 3 weeks by IV infusion (as a reference group, n=42) for 18 months. This study used the placebo arm of the APOLLO study as an external control arm (n=77) for the primary endpoint and most other efficacy endpoints. The primary endpoint was the change from baseline in mNIS+7 at 9 months.²

As stated in the Prescribing Information, vutrisiran should be administered by a healthcare professional.¹ Given the infrequent dosing schedule, administration by a healthcare professional was deemed the best way to ensure consistent, proper injection technique.

ABBREVIATIONS

hATTR-PN = hereditary transthyretin amyloidosis with polyneuropathy; IV = intravenous; mNIS+7 = modified Neuropathy Impairment Score +7.

Updated 20 December 2024

REFERENCES

1. AMVUTTRA (vutrisiran) Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
2. Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. *Amyloid*. 2023;30(1):18-26. doi:10.1080/13506129.2022.2091985